JAMA surgery
-
Randomized Controlled Trial Multicenter Study
A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial.
Necrotizing soft-tissue infections (NSTI) have high morbidity and mortality rates despite aggressive surgical debridement and antibiotic therapy. AB103 is a peptide mimetic of the T-lymphocyte receptor, CD28. We hypothesized that AB103 will limit inflammatory responses to bacterial toxins and decrease the incidence of organ failure. ⋯ AB103 is a safe, promising new agent for modulation of inflammation after NSTI. Further study is warranted to establish efficacy.